TSC-101
TScan Cuts 75% of Workforce and Pauses Phase 3 Trial
TScan Therapeutics Inc. (Nasdaq: TCRX) is eliminating approximately 75% of its workforce and pausing further enrollment in its Phase 3 ALLOHA-2 trial because it does not have sufficient capital to complete the study. The company announced the strategic reorganization on September 2. TScan will redirect its resources toward two preclinical in-vivo T-cell receptor-engineered T-cell therapy…
